PCM
INDV icon

Polymer Capital Management’s Indivior Pharmaceuticals INDV Stock Holding History

Polymer Capital Management’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-8,240
Closed -$251K – 802
2026
Q1 		$251K Sell
8,240
-27,254
-77% -$900K 0.03% 681
2025
Q4 		$1.27M Buy
35,494
+25,632
+260% +$783K 0.13% 173
2025
Q3 		$238K Buy
+9,862
New +$206K 0.03% 667

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Polymer Capital Management's INDV Position: Q2 2026 in Review

Polymer Capital Management sold out of Indivior Pharmaceuticals (INDV) in Q2 2026, closing a stake of 8,240 shares — an estimated $251K sold.

Polymer Capital Management first reported a position in INDV in Q3 2025 and held it in 3 quarters. The position peaked at $1.27M in Q4 2025. 339 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Polymer Capital Management reported no remaining Indivior Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Polymer Capital Management sold 8,240 Indivior Pharmaceuticals shares in Q2 2026, an estimated $251K.
  • Polymer Capital Management first reported a position in Indivior Pharmaceuticals in Q3 2025 and held it in 3 quarters.
  • Polymer Capital Management's Indivior Pharmaceuticals position peaked at $1.27M in Q4 2025.
  • 339 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Polymer Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.